[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344405-105":59,"doc-detail-344405-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-report-an-exceptional-response-to-a-novel-immunotherapy-based-combination-treatment-for-resected-pancreatic-ductal-adenocarcinoma-with-recurrence-to-the-abdominal-wall","Case Report - An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the abdominal wall","","Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high recurrence after resection and limited benefit from current immuno- or immunocombination therapies. The study highlights leukemia inhibitory factor (LIF) as a driver of an immunosuppressive tumor microenvironment mediated in part by pro-tumoral (M2-like) tumor-associated macrophages. It describes a patient with recurrent PDAC involving the abdominal wall and peritoneum who achieved immediate complete remission after investigational MSC-1 plus anti-PD-L1 and standard chemotherapy, and discusses immunological mechanisms behind the response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-an-exceptional-response-to-a-novel-immunotherapy-based-combination-treatment-for-resected-pancreatic-ductal-adenocarcinoma-with-recurrence-to-the-abdominal-wall/344405/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-an-exceptional-response-to-a-novel-immunotherapy-based-combination-treatment-for-resected-pancreatic-ductal-adenocarcinoma-with-recurrence-to-the-abdominal-wall/344405.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why has immunotherapy been limited in pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":112,"@type":113},"Current immuno- or immunocombination therapies have not shown significant improvements in progression-free or overall survival, likely due to a highly immunosuppressive tumor microenvironment (TME).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does leukemia inhibitory factor (LIF) play in PDAC?",{"text":117,"@type":113},"LIF contributes to immunosuppression in the TME by inhibiting T-cell influx and promoting pro-tumoral (M2-like) tumor-associated macrophages. It also supports processes such as epithelial-mesenchymal transition (EMT) involved in metastasis formation.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment led to complete remission in the reported patient?",{"text":121,"@type":113},"The patient with recurrent PDAC received an investigational regimen combining MSC-1 (anti-LIF) with anti-PD-L1 and standard-of-care chemotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344405,1790209859,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","TYPE Case Report  \nPUBLISHED 23 February 2026 DOI 10.3389/fonc.2026.1649850  \nOPEN ACCESS  \nEDITED BY  \nMoon Nyeo Park,  \nKyung Hee University, Republic of Korea  \nREVIEWED BY  \nAntonella Argentiero,  \nNational Cancer Institute Foundation (IRCCS), Italy  \nQian Yu,  \nThe Afﬁliated Hospital of Qingdao University, China  \nZhuozhuo Wu,  \nShanghai Jiao Tong University, China  \n*CORRESPONDENCE  \nThomas Enzler  \n[tenzler@med.umich.edu](tenzler@med.umich.edu)  \nRECEIVED 19 June 2025  \nREVISED 02 February 2026  \nACCEPTED 04 February 2026  \nPUBLISHED 23 February 2026  \nCITATION  \nEnzler T, Tweedy S, Holmes I and Lamps LW (2026) Case Report: An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductaladenocarcinoma with recurrence to the abdominal wall.  \nFront. Oncol. 16:1649850 .  \ndoi: 10.3389/fonc.2026.1649850  \nCOPYRIGHT  \n© 2026 Enzler, Tweedy, Holmes and Lamps. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: An exceptional response to a novel immunotherapy-based combination treatment forresected pancreatic ductaladenocarcinoma with recurrence to the abdominal wall  \nThomas Enzler 1*, Sara Tweedy1,2, Isabella Holmes 2 and Laura W. Lamps 2  \n1 Department of Medicine, University of Michigan, Ann Arbor, MI, United States, 2 Department of Pathology, University of Michigan, Ann Arbor, MI, United States  \nPancreatic ductal adenocarcinoma (PDAC) is a difﬁcult-to-treat cancer with a 5-year survival rate of only 13% . Intense chemotherapies are needed to control the disease. Surgical resection, if possible, is the only curative approach. However, recurrence rates are high. The inclusion of immune checkpoint inhibitors in treatment hasn ’t shown beneﬁt, most likely because of the cancer ’s highly immunosuppressive tumor microenvironment (TME) . Leukemia Inhibitory Factor (LIF) is a cytokine that contributes to this profound immunosuppression, which is thought to be at least partly mediated by pro-tumoral (M2-like) tumorassociated macrophages (TAMs) . Those macrophages harbor LIF receptors on their surface. The addition of the anti-LIF antibody MSC-1 to a combination of anti-programmed death-ligand 1 (anti-PD-L1) and chemotherapy has shown encouraging preclinical results, successfully reversing pro-tumoral TAMs into anti-tumoral (M1-like) macrophages. Here, we report a patient with recurrent PDAC in the abdominal wall and peritoneum, that immediately went into complete remission after receiving an investigational treatment with MSC-1 and anti-PD-L1 combined with standard-of-care chemotherapy. We discuss immunological mechanisms that may have contributed to the impressive treatment response.  \nKEYWORDS  \nPDAC, cutaneous/subcutaneous metastasis, immunochemotherapy including anti-LIF, conversion of M2 to M1 macrophages, complete response  \nIntroduction  \nPDAC is one of the deadliest solid cancers. Even if the disease is resected and standardof-care treatment protocols have been applied, recurrence rates are high, and, ultimately, most patients will die from the disease (1) . Current chemotherapies have limited efﬁcacy. Accumulating toxicities often require dose reductions or even omission of agents, further  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \ndiminishing treatment responses. To date, immuno- or immunocombination therapies have not been shown to signiﬁcantly improve progression-free or overall survival (2) . Leukemia Inhibitory Factor (LIF) is a cytokine belonging to the interleukin- 6 superfamily. It is involved in diverse physiological and pathophysiological p","cbCaify80zWgL3Ja","https://ap.wps.com/l/cbCaify80zWgL3Ja","pdf",776172,"English","# Introduction\n# Case presentation","[{\"question\":\"Why has immunotherapy been limited in pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"Current immuno- or immunocombination therapies have not shown significant improvements in progression-free or overall survival, likely due to a highly immunosuppressive tumor microenvironment (TME).\"},{\"question\":\"What role does leukemia inhibitory factor (LIF) play in PDAC?\",\"answer\":\"LIF contributes to immunosuppression in the TME by inhibiting T-cell influx and promoting pro-tumoral (M2-like) tumor-associated macrophages. It also supports processes such as epithelial-mesenchymal transition (EMT) involved in metastasis formation.\"},{\"question\":\"What treatment led to complete remission in the reported patient?\",\"answer\":\"The patient with recurrent PDAC received an investigational regimen combining MSC-1 (anti-LIF) with anti-PD-L1 and standard-of-care chemotherapy.\"}]","Case Report - An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the abdominal wall | PDF",1790053638,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49a6fa9a0d42a1bc3f2b493b28aaadae.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b50d057693487b694f833384250727cd.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8028d8d9daad4945b15e70e2fc1170f.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/facfcc0406a33bd061d1f721e616c262.webp",980,1385]